Anti-CoV-S[679-833]-H7 antibody

Reference: PTXCOV-A516C
Size

100µg

Brand

Product type

Clonality

Product nameAnti-CoV-S[679-833]-H7 antibody
SpeciesHuman
Expression systemMammalian
Molecular weight150kDa
Purity90%
BufferPBS, pH7,5
FormLiquid
Delivery conditionDry ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteogenix
ApplicationsELISA,WB
ReferencePTXCOV-A516C
NoteFor research use and in vitro diagnostic only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody
TargetRecombinant CoV-S[679-833] fragment

Description of Anti-CoV-S[679-833]-H7 antibody

General information on Anti-CoV-S[679-833]-H7 antibody

The anti-CoV-S[679-833]-H7 antibody was shown to possess a very strong affinity towards the S1/S2 border region of the spike glycoprotein found in SARS-CoV-2. The antibody was developed by phage display screening of our extremely diverse COVID-19 human antibody library (LiAb-SFCOVID-19™) for relevant binders against the spike fragment CoVs[679-833]. This fragment is predicted to contain the furin cleavage site, a vital domain for viral internalization in the COVID-19 pathology. In detail, this site is located between the S1 and S2 subunits of the spike glycoprotein and it is prone to catalysis by ubiquitous human proteases (furin). Once cleaved, this process exposes the S2 domain which, in turn, initiates the process of fusion between the viral and the human epithelial membranes.
This region thus represents the second stage of infection by SARS-CoV-2 and it is preceded only by the recognition and binding of the angiotensin-converting enzyme 2 (ACE2) receptor. For this reason, the antibody represents an opportunity to better understand the mechanism of infection in SARS-CoV-2 and to determine if the region containing the furin cleavage site could be a potentially interesting new therapeutic target to prevent the onset or treat COVID-19 pneumonia.
The antibody has been thoroughly validated against its intended target – CoV-S[679-833] – through enzyme-linked immunosorbent assay (ELISA). Moreover, no cross-reactivity was found against other regions of SARS-CoV-2 spike glycoprotein indicating the specificity of the newly developed reagent. The new fully human IgG antibody was also shown to be stable and easily produced with high yields in XtenCHO™, a transient recombinant mammalian system with optimal productivity.

SDS-PAGE for Anti-CoV-S[679-833]-H7 antibody

Anti-CoV-S[679-833]-H7 antibody, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Anti-CoV-S[679-833]-H7 antibody”

Your email address will not be published. Required fields are marked *

Related products

Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 189$

Contact us

Send us a message from the form below







    Cart (3 Items)

    size:

    300µL

    Availability: In Stock
    1 × $136.85
    Size:

    100ug

    Availability: In Stock
    1 × $411.00
    Size:

    100ug

    Availability: In Stock
    1 × $411.00